Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes
M Arakawa-Todo, T Yoshizawa, K Zennami… - Anticancer …, 2013 - ar.iiarjournals.org
Patients with progressive renal cell carcinoma who undergo sunitinib treatment, experience
many adverse events (AEs), including thrombopenia and hypertension. Dose reduction or …
many adverse events (AEs), including thrombopenia and hypertension. Dose reduction or …
Drug interaction between sunitinib and cimetidine and contribution of the efflux transporter ATP-binding cassette C2 to biliary excretion of sunitinib in rats
The present study investigated the effect of the H 2 antagonist cimetidine on the pharmacokinetics
of a multi-targeted receptor tyrosine kinase (RTK) inhibitor, sunitinib, in Sprague-…
of a multi-targeted receptor tyrosine kinase (RTK) inhibitor, sunitinib, in Sprague-…
Usefulness of implementing comprehensive pharmaceutical care for metastatic renal cell carcinoma outpatients treated with pazopanib
M Todo, S Shirotake, K Nishimoto… - Anticancer …, 2019 - ar.iiarjournals.org
Background: Pazopanib is an effective treatment option for renal cell carcinoma (RCC).
However, the therapy is often limited by the appearance of adverse events (AEs), including …
However, the therapy is often limited by the appearance of adverse events (AEs), including …
Improvement of treatment outcomes after implementation of comprehensive pharmaceutical care in breast cancer patients receiving everolimus and exemestane
M Todo, S Ueda, S Osaki, I Sugitani… - Die Pharmazie-An …, 2018 - ingentaconnect.com
Combination therapy with everolimus and an aromatase inhibitor such as exemestane is an
effective treatment option for advanced or recurrent breast cancer. However, the therapy is …
effective treatment option for advanced or recurrent breast cancer. However, the therapy is …
Efficacy and safety of nivolumab for metastatic renal cell carcinoma: A Japanese single institutional retrospective study
S Shirotake, H Kondo, T Hayashi, T Okabe… - lung - saitama-med.repo.nii.ac.jp
[Purpose] The phase III CheckMate 025 trial showed that nivolumab improved clinical benefit
in advanced renal cell carcinoma. Herein, we report the efficacy and safety of nivolumab for …
in advanced renal cell carcinoma. Herein, we report the efficacy and safety of nivolumab for …
Lack of contribution of multidrug resistance-associated protein and organic anion-transporting polypeptide to pharmacokinetics of regorafenib, a novel multi-kinase …
K Hotta, J Ueyama, Y Tatsumi, I Tsukiyama… - Anticancer …, 2015 - ar.iiarjournals.org
We investigated whether hepatic multidrug resistance-associated protein 2 (ABCC2) is
involved in the hepatobiliary excretion of regorafenib, a novel multi-kinase inhibitor, using …
involved in the hepatobiliary excretion of regorafenib, a novel multi-kinase inhibitor, using …
当院における転移性腎細胞癌に対するニボルマブの初期使用経験
城武卓， 近藤秀幸， 林泰樹， 岡部尚志， 高橋崇志… - 埼玉医科大学 …, 2019 - jstage.jst.go.jp
… We would like to thank the pharmacist, Maki Todo, for carefully managing adverse events
for the mRCC patients, and the urologist, Tsukasa Masuda, for collecting the patient data. …
for the mRCC patients, and the urologist, Tsukasa Masuda, for collecting the patient data. …